FORM 4

UNITED STATES SECU

Washington, D.C. 20549

KH	IES	AND	EX	CHAI	NGE	CO	MM	1551	U

OWB APPROVAL										
OMB Number:	3235-0287									
Estimated average hurden										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wai Conrad				2. Issuer Name and Ticker or Trading Symbol CLOVER HEALTH INVESTMENTS, CORP. /DE [CLOV]						(Che	5. Relationship of Reportin (Check all applicable) Director Officer (give title			10% Owner					
(Last) (First) (Middle) C/O CLOVER HEALTH INVESTMENTS, CORP. 30 MONTGOMERY STREET				3. Date of Earliest Transaction (Month/Day/Year) 12/14/2024								Officer (give title Other (specify below) CEO, Counterpart Health							
(Street) JERSEY CITY NJ 07302 (City) (State) (Zip)														Line)	Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)					tion 2A. Deemed 3. Execution Date, if any Co			3. Transa	Transaction Disposed Of (D) (Instr. 3, 2) Code (Instr. 5)			A) or	5. Amo Securi Benefi Owned	ount of ties cially I Following	Form: Dir	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Class A Common Stock 12/14/2					2024		Code	v	(D)		Price \$3.11	(Instr.	68,533	D		(Instr. 4)			
		Та									osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	3A. Deemed Execution Date, if any (Month/Day/Year)		Transaction of Code (Instr. 8) Sc Ac (A Di of		osed) r. 3, 4	Expirat	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Own Forn Direc or In (I) (Ir	ership n: ct (D) direct nstr. 4)	Benefici Owners (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amo or Num of Shar	ber					

Explanation of Responses:

1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on December 14, 2024, of 6.25% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on March 14, 2022. The remaining RSUs vest quarterly in equal installments of 6.25%, with a final vesting date occurring on March 14, 2026, subject to the continued service of the Reporting Person on each such vesting date.

Remarks:

/s/ Peter J. Rivas as attorneyin-fact for Conrad Wai

12/17/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.